Increased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Increased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018

Published:2020-12-05 Issue:1 Volume:56 Page:46-52
ISSN:0036-5521
Container-title:Scandinavian Journal of Gastroenterology
language:en
Short-container-title:Scandinavian Journal of Gastroenterology

Author:

Kristjánsson Valdimar B.¹,Lund Sigrún H.¹,Gröndal Gerður¹²,Sveinsdóttir Signý V.²,Agnarsson Hjálmar R.²,Jónasson Jón G.¹³,Björnsson Einar S.¹²⁴

Affiliation:

1. Faculty of Medicine, University of Iceland, Reykjavík, Iceland

2. Department of Internal Medicine, National University Hospital, Reykjavík, Iceland

3. Department of Pathology, National University Hospital, Reykjavík, Iceland

4. Division of Gastroenterology and Hepatology, Department of Internal Medicine, National University Hospital, Reykjavík, Iceland

Publisher

Informa UK Limited

Subject

Gastroenterology

Link

https://www.tandfonline.com/doi/pdf/10.1080/00365521.2020.1854847

Reference34 articles.

1. Colitis associated with biological agents

2. The late adverse events of rituximab therapy – rare but there!

3. Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis

4. Rituximab in multiple sclerosis

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. B-cell Depletion Therapy in Pediatric Neuroinflammatory Disease;Current Neurology and Neuroscience Reports;2024-09-11

2. Review of dermatologic drugs relevant to inflammatory bowel disease;JAAD Reviews;2024-09

3. Successful Treatment of Rituximab-Induced Crohn's Disease With Ustekinumab;ACG Case Reports Journal;2024-07

4. Mesenteric Lymphatic B Cells Migrate to the Intestine and Aggravate DSS-Induced Colitis via the CXCR5–CXCL13 Axis;Biology;2024-05-06

5. Psoriasiform dermatitis following ocrelizumab in relapsing-remitting multiple sclerosis: Case report and literature review;Multiple Sclerosis Journal;2024-02-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3